Global News
15 Feb 2023
Jubilant Therapeutics receives Orphan Drug Designation for PRMT5 inhibitor – JBI-778
The drug is used for the treatment of Glioblastoma Multiforme Jubilant Therapeutics, a clinical-stage biopharmaceutical company advancing small molecule precision…
